Vibegron, a Novel Potent and Selective β 3 -Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Vibegron, a Novel Potent and Selective β 3 -Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study

Published:2018-05 Issue:5 Volume:73 Page:783-790
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Yoshida Masaki^ORCID,Takeda Masayuki,Gotoh Momokazu,Nagai Shinji,Kurose Takafumi

Publisher

Elsevier BV

Subject

Urology

Reference30 articles.

1. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society;Abrams;Am J Obstet Gynecol,2002

2. Neurogenic Bladder Society Committee. An epidemiological survey of overactive bladder symptoms in Japan;Homma;BJU Int,2005

3. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study;Irwin;Eur Urol,2006

4. Prevalence and burden of overactive bladder in the United States;Stewart;World J Urol,2003

5. Gruppo Interdisciplinare di Studio Incontinenza Urinaria. Impact of urinary incontinence and overactive bladder on quality of life;Chiaffarino;Eur Urol,2003

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiological and metabolic functions of the β3-adrenergic receptor and an approach to therapeutic achievements;Journal of Physiology and Biochemistry;2024-08-15

2. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder;Neurourology and Urodynamics;2024-07-15

3. The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder;Journal of Urology;2024-07

4. Efficacy and safety of Vibegron for the treatment of residual overactive bladder symptoms after laser vaporization of the prostate: A single‐center prospective randomized controlled trial (VAPOR TRIAL);LUTS: Lower Urinary Tract Symptoms;2024-07

5. Urinary Incontinence Medications: Patient-Initiated Concerns in Primary Care;Urogynecology;2024-06-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3